Suppression of fibroblast activity by an inhibitor of dipeptidyl peptidase IV. A possible therapeutic strategy for rheumatoid arthritis

被引：0
|
作者：
Williams, YN
Sugita, T
Nosaka, Y
Kubota, T
机构：
[1] Tokyo Med & Dent Univ, Grad Sch Allied Hlth Sci, Bunkyo Ku, Tokyo 1138519, Japan
[2] Discovery Res Lab, Osaka, Japan
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2003年 / 21卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：685 / 685
页数：1
相关论文
共 50 条
  • [41] Levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients
    Suncica Buljevic
    Dijana Detel
    Lara Baticic Pucar
    Radovan Mihelic
    Tomislav Madarevic
    Branko Sestan
    Jadranka Varljen
    Rheumatology International, 2013, 33 : 2867 - 2874
  • [42] Brensocatib (an oral, reversible inhibitor of dipeptidyl peptidase-1) attenuates disease progression in two animal models of rheumatoid arthritis
    Mcdonald, Patrick P.
    Leifer, Franziska Graf
    Basso, Jessica
    Lasala, Dan
    Li, Dedong
    Chen, Kuan-Ju
    Zhang, Jimin
    Perkins, Walter R.
    Cipolla, David C.
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [43] Reduced salivary amylase activity in metabolic syndrome patients with obesity could be improved by treatment with a dipeptidyl peptidase IV inhibitor
    Ittichaicharoen, Jitjiroj
    Phrommintikul, Arintaya
    Chattipakorn, Nipon
    Chattipakorn, Siriporn
    CLINICAL ORAL INVESTIGATIONS, 2018, 22 (09) : 3113 - 3120
  • [44] Reduced salivary amylase activity in metabolic syndrome patients with obesity could be improved by treatment with a dipeptidyl peptidase IV inhibitor
    Jitjiroj Ittichaicharoen
    Arintaya Phrommintikul
    Nipon Chattipakorn
    Siriporn Chattipakorn
    Clinical Oral Investigations, 2018, 22 : 3113 - 3120
  • [45] Gold Nanoparticle-Based Colorimetric and Electrochemical Methods for Dipeptidyl Peptidase-IV Activity Assay and Inhibitor Screening
    Xia, Ning
    Wang, Xin
    Wang, Xiaojin
    Zhou, Binbin
    MATERIALS, 2016, 9 (10)
  • [46] Serum dipeptidyl peptidase IV activity in patients with angiotensin-converting enzyme inhibitor-associated angioedema.
    Lefebvre, J
    Murphey, LJ
    Hartert, TV
    Shan, RJ
    Simmons, WH
    Brown, NJ
    CIRCULATION, 2001, 104 (17) : 450 - 450
  • [47] Comment on: levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients
    Sahoo, JayaPrakash
    Kamalanathan, Sadishkumar
    RHEUMATOLOGY INTERNATIONAL, 2015, 35 (04) : 757 - 758
  • [48] Comment on: levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients
    JayaPrakash Sahoo
    Sadishkumar Kamalanathan
    Rheumatology International, 2015, 35 : 757 - 758
  • [49] Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: Nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1
    Duffy, Nicola A.
    Green, Brian D.
    Irwin, Nigel
    Gault, Victor A.
    McKillop, Aine M.
    O'Harte, Finbarr P. M.
    Flatt, Peter R.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 568 (1-3) : 278 - 286
  • [50] Acute onset of rheumatoid arthritis associated with administration of a dipeptidyl peptidase-4 (DPP-4) inhibitor to patients with diabetes mellitus
    Sasaki T.
    Hiki Y.
    Nagumo S.
    Ikeda R.
    Kimura H.
    Yamashiro K.
    Gojo A.
    Saito T.
    Tomita Y.
    Utsunomiya K.
    Diabetology International, 2010, 1 (2) : 90 - 92
12345